Phase 2
Completed N=118
Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay
Source: ClinicalTrials.gov NCT02956616 ↗Enrolled (actual)
118
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcomePrimary: Discharge on Postoperative Day #2 — 5; 2 Participants
Summary
To determine whether women randomized to an enhanced recovery program will have improved postoperative outcomes including improved breastfeeding initiation and continuation, reduction in hospital length of stay without compromising patient satisfaction in comparison to standard postoperative recovery interventions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Discharge on Postoperative Day #2 |
5; 2 | — |
| SECONDARY Postoperative Pain Medication Requirement |
117.16; 119.38 | — |
| SECONDARY Breastfeeding Initiation |
39; 29; 4; 2; 15; 29 | — |
| SECONDARY Postoperative Length of Hospital Stay |
73.58; 75.50 | — |
Eligibility Criteria
Inclusion Criteria
- Women undergoing a non-urgent or elective cesarean delivery >37 weeks gestation
Exclusion Criteria
- Women undergoing an urgent or emergent cesarean birth
- Women less than 18 years old
- Patients receiving general anesthesia
- Abnormally adherent placenta (Placenta Accreta) or expected excessive blood loss (Placenta accreta)
- Pre-existing essential hypertension or hypertensive disorders of pregnancy (preeclampsia, eclampsia, HELLP)
- Chronic or acute renal impairment
- Bleeding disorders or platelet dysfunction
- Peptic ulcer disease or gastrointestinal bleeding
- Known hypersensitivity to ketorolac (toradol)
- Active infection at the time of cesarean
- Cesarean birth prior to 37 weeks
- Women in significant pain in labor
Data sourced from ClinicalTrials.gov (NCT02956616). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.